Taysha Gene Therapies to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 16

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) will report its second-quarter financial results for the period ending June 30, 2021, on August 16, 2021, at 8:00 AM ET. This pivotal-stage gene therapy company focuses on AAV-based therapies targeting monogenic central nervous system diseases. The company aims to provide updates on their progress and future outlook during the conference call.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the second quarter ended June 30, 2021, and host a corporate update conference call and webcast on Monday, August 16, 2021, at 8:00 AM Eastern Time.

Conference Call Details
Monday, August 16, at 8:00 AM Eastern Time / 7:00 AM Central Time
Toll Free:				877-407-0792
International:				201-689-8263
Conference ID:				13722197
Webcast:				https://ir.tayshagtx.com/news-events/events-presentations

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005807/en/

FAQ

When will Taysha Gene Therapies report its Q2 2021 financial results?

Taysha Gene Therapies will report its Q2 2021 financial results on August 16, 2021, at 8:00 AM Eastern Time.

What is the conference call ID for the Taysha Gene Therapies update?

The conference call ID for the Taysha Gene Therapies corporate update is 13722197.

How can I access the webcast for Taysha Gene Therapies' financial results?

The webcast can be accessed at https://ir.tayshagtx.com/news-events/events-presentations.

What is Taysha Gene Therapies' focus area?

Taysha Gene Therapies focuses on developing AAV-based gene therapies for treating monogenic diseases of the central nervous system.